Hôpital le Vinatier
ch-le-vinatier.frTotal trials
102
Active
36
Phase 3
1
Total enrollment
14,759
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Cannabidiol oral oil | — | — | — | — | — | 1 |
Next readouts
- 2026-09-30
Top conditions
- Schizophrenia26
- Autism Spectrum Disorder8
- Depression4
- 22q11.2 Deletion Syndrome3
- Transcranial Direct Current Stimulation2
- Alcohol Use Disorder2
- Mental Disorders2
- Autism2
Frequently asked questions about Hôpital le Vinatier
- How many clinical trials does Hôpital le Vinatier have on ClinicalTrials.gov?
- Hôpital le Vinatier is listed as the lead sponsor on 102 clinical trials in ClinicalTrials.gov, 36 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Hôpital le Vinatier's trials are in Phase 3?
- 1 of Hôpital le Vinatier's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does Hôpital le Vinatier focus on?
- Hôpital le Vinatier's most-studied conditions on ClinicalTrials.gov are Schizophrenia, Autism Spectrum Disorder, Depression, 22q11.2 Deletion Syndrome, Transcranial Direct Current Stimulation.
- When are Hôpital le Vinatier's next clinical trial readouts?
- Hôpital le Vinatier has 1 upcoming primary-completion readout tracked here; the soonest is “Cannabidiol for Reducing Drinking in Alcohol Use Disorder”, expected around 2026-09-30.